425 related articles for article (PubMed ID: 37835383)
1. Estrogen Receptor Signaling in Breast Cancer.
Miziak P; Baran M; Błaszczak E; Przybyszewska-Podstawka A; Kałafut J; Smok-Kalwat J; Dmoszyńska-Graniczka M; Kiełbus M; Stepulak A
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835383
[TBL] [Abstract][Full Text] [Related]
2. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
Pagliuca M; Donato M; D'Amato AL; Rosanova M; Russo AOM; Scafetta R; De Angelis C; Trivedi MV; André F; Arpino G; Del Mastro L; De Laurentiis M; Puglisi F; Giuliano M
Crit Rev Oncol Hematol; 2022 Dec; 180():103861. PubMed ID: 36374739
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
Haines CN; Wardell SE; McDonnell DP
Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM; Dickler MN
Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
[TBL] [Abstract][Full Text] [Related]
6. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
7. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
[TBL] [Abstract][Full Text] [Related]
10. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a multi-target compound for estrogen receptor-positive (ER
Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
[TBL] [Abstract][Full Text] [Related]
12. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
13. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
14. Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.
Bai JW; Wei M; Li JW; Zhang GJ
Front Pharmacol; 2020; 11():924. PubMed ID: 32636747
[TBL] [Abstract][Full Text] [Related]
15. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.
Jiang CF; Shi ZM; Li DM; Qian YC; Ren Y; Bai XM; Xie YX; Wang L; Ge X; Liu WT; Zhen LL; Liu LZ; Jiang BH
Mol Cancer; 2018 Apr; 17(1):83. PubMed ID: 29685157
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
19. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]